



1646

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-1242)

In the Application of:

Ward, et al.  
Serial No.: 09/936,964  
Filing Date: March 15, 2000  
For: Anti-p53 Antibodies

)  
Examiner: TBA  
)  
Group Art Unit: 1646  
)  
Confirmation No.: 4441  
)

TRANSMITTAL LETTER

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

Dear Sir:

FEB 06 2003


In regard to the above identified application,

TECH CENTER 1600/2000

1. We are transmitting herewith the attached:
  - a) Information Disclosure Statement;
  - b) PTO Form 1449 and 14 references cited therein; and
  - c) return receipt postcard.
2. With respect to fees:
  - a) A check in the amount of \$180.00 is enclosed.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on January 29, 2003.

Respectfully submitted,

Date: January 29, 2003



Michael S. Greenfield  
Registration No. 37,142

#8  
PATENTJW  
S/11/03IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-1242)

In the Application of:

Ward, et al.

Serial No.: 09/936,964

Examiner: TBA

Filing Date: March 15, 2000

Group Art Unit: 1646

For: Anti-p53 Antibodies

Confirmation No.: 4441

## INFORMATION DISCLOSURE STATEMENT

RECEIVED

FEB 06 2003

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

TECH CENTER 1600/2900

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form 1449.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

## OTHER DOCUMENTS

1. Ko, Linda J. and Prives, Carol, "p53: Puzzle and Paradigm," Department of Biological Sciences, Columbia University, New York 10027 USA, Genes and Development 10: 1054-1072 (1996).

180.00 0P

00000143 09936964

02/04/2003 ANABII

01 FC:1806

## CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, Washington D.C. 20231, on January 29, 2003.

Date: January 29, 2003


  
Michael S. Greenfield

2. Soussi, Thierry and May, Pierre, "Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look," *J. Mol. Biol.* (1996) 260, 623-637.
3. Lubin, et al., "Analysis of p53 Antibodies in Patients with Various Cancers Define B-Cell Epitopes of Human p53: Distribution of Primary Structure and Exposure on Protein Surface," 5872-5876, December 15, 1993.
4. Computer Corner, "Methods and Reagents, Fidelity of DNA polymerases for PCR," *TIBS* 20 - August 1995.
5. Nissim, et al., "Antibody Fragments from a 'Single Pot' Phage Display Library as Immunochemical Reagents," *The EMBO Journal*, vol. 13, no. 3, pp. 692-698 (1994).
6. Chang, Bernard and Casali, Paolo, "The CDR1 Sequences of a Major Proportion of Human Germline Ig V<sub>H</sub> Genes are Inherently Susceptible to Amino Acid Replacement," *Innunogolgy Today*, Vol. 15, No. 8 (1994).
7. Clark, et al., "Isolation of Human anti-c-erbB-2 Fabs from a Lymph Node-Derived Phage display library," *Clin Exp Immunol* 109: 166-174 (1997).
8. Ward, et al., "Retrieval of Human Antibodies from Phage-Display Libraries Using Enzymatic Cleavage," *Journal of Immunological Methods* 189 (1996) 73-82.
9. Chomczynski, Piotr and Sacchi, Nicoletta, "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Choloroform Extraction," *Analytical Biochemistry* 16, 156-159 (1987).
10. Coomber, et. al., "Characterisation and Clinicopathological Correlates of Serum Anti-p53 Antibodies in Breast and Colon Cancer," *J Cancer Res Clin Oncol* (1996) 122: 757-762.
11. Abrams, et al., "Optimal Strategies for Developing Human-Human Monoclonal Antibodies," *Methods in Enzymology*, vol. 121 (1986).
12. Winter, et al., "Development of Antibodies against p53 in Lung Cancer Patients Appears To Be Dependent on the Type of p53 Mutation," *Cancer Research* 52, 4168-4174, August 1, 1992.
13. Vogelstein, Bert and Kinzler, Kenneth W., "p53 Function and Dysfunction," *Cell*, Vol. 70, 532-526, August 21, 1992.
14. Hollstein, et al., "p53 Mutations in Human Cancers," *Science*, vol. 253, 5 July 1991.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff**

Date: January 29, 2003

By:



Michael S. Greenfield  
Reg. No. 37,142

Telephone: 312-913-0001  
Facsimile: 312-913-0002

**McDonnell Boehnen Hulbert & Berghoff**  
300 South Wacker Drive, 32<sup>nd</sup> Floor  
Chicago, IL 60606

O I P E

FEB 03 2003

SEARCHED & TRADEMADE INDEXED

		Genes are Inherently Susceptible to Amino Acid Replacement," <i>Innunogolgy Today</i> , Vol. 15, No. 8 (1994).
	7.	Clark, et al., "Isolation of Human anti-c-erbB-2 Fabs from a Lymph Node-Derived Phage display library," <i>Clin Exp Immunol</i> 109: 166-174 (1997).
	8.	Ward, et al., "Retrieval of Human Antibodies from Phage-Display Libraries Using Enzymatic Cleavage," <i>Journal of Immunological Methods</i> 189 (1996) 73-82.
	9.	Chomczynski, Piotr and Sacchi, Nicoletta, "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Choloroform Extraction," <i>Analytical Biochemistry</i> 16, 156-159 (1987).
	10.	Coomber, et. al., "Characterisation and Clinicopathological Correlates of Serum Anti-p53 Antibodies in Breast and Colon Cancer," <i>J Cancer Res Clin Oncol</i> (1996) 122: 757-762.
	11.	Abrams, et al., "Optimal Strategies for Developing Human-Human Monoclonal Antibodies," <i>Methods in Enzymology</i> , vol. 121 (1986).
	12.	Winter, et al., "Development of Antibodies against p53 in Lung Cancer Patients Appears To Be Dependent on the Type of p53 Mutation," <i>Cancer Research</i> 52, 4168-4174, August 1, 1992.
	13.	Vogelstein, Bert and Kinzler, Kenneth W., "p53 Function and Dysfunction," <i>Cell</i> , Vol. 70, 532-526, August 21, 1992.
	14.	Hollstein, et al., "p53 Mutations in Human Cancers," <i>Science</i> , vol. 253, 5 July 1991.
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

RECEIVED  
FEB 06 2003  
TECH CENTER 1600/2900

FORM PTO-144  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

01-1242

Serial No.

09/936,964

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

RECEIVED

FEB 06 2003

TECH CENTER 1600/2900

Applicant:

Ward, et al.

Filing Date:

March 15, 2000

Group:

1646

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

1.	Ko, Linda J. and Prives, Carol, "p53: Puzzle and Paradigm," Department of Biological Sciences, Columbia University, New York 10027 USA, Genes and Development 10: 1054-1072 (1996).
2.	Soussi, Thierry and May, Pierre, "Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look," J. Mol. Biol. (1996) 260, 623-637.
3.	Lubin, et al., "Analysis of p53 Antibodies in Patients with Various Cancers Define B-Cell Epitopes of Human p53: Distribution of Primary Structure and Exposure on Protein Surface," 5872-5876, December 15, 1993.
4.	Computer Corner, "Methods and Reagents, Fidelity of DNA polymerases for PCR," TIBS 20 - August 1995.
5.	Nissim, et al., "Antibody Fragments from a 'Single Pot' Phage Display Library as Immunochemical Reagents," The EMBO Journal, vol. 13, no. 3, pp. 692-698 (1994).
6.	Chang, Bernard and Casali, Paolo, "The CDR1 Sequences of a Major Proportion of Human Germline Ig V <sub>H</sub>